Home

In Defense of INmune

I invest in "public venture capital" stocks. The typical company around here is early stage, has no revenue and is burning cash on a...

First U.S. Patent Issues on Hancock Jaffe VenoValve

TW's Take: an incremental positive for HJLI. Stock needs to get above $7 and clean out the last of the sellers from the recent...

Sequans Announces $50 Million Financing to Strengthen Balance Sheet

TW's Take: Lynrock Lake is a very high quality, fundamental investor and this financing is a strong endorsement for Sequans. SQNS is entering a...

Lithe Audio Launches First WiSA Certified Dolby Atmos Ceiling Speakers

TW's Take: the WiSA ecosystem continues to grow. I'm convinced that integration with Sonos is coming soon, which could dramatically accelerate the market for...

Amryt Announces the Appointment of Sheila Frame as President Americas

DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel...

Trading Blog, April 6, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic

TW's Take: with Covid, and its various strands, destined to be here for a while, this is a nice development in a low cost...

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

TW's Take: approval of the IDE in under 30 days demonstrates both the need for the product as well as the robust data provided...

A Catalyst Filled Quarter Lies Around The Corner

My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It...

Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary...

TW's Take: on the surface a nice positive, adding a $24M product to the portfolio. Look forward to understanding the terms of this transaction...

LEXAGENE PROVIDES CORPORATE UPDATE

TW's Take: while disappointed in the stretched timeline for EUA approval, this is a very positive update. The vet market is sufficiently large to...

Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor...

TW's Take: LP-184 is a very potent molecule. Combined with the resources of RADR, Lantern continues to find more potential treatments for the drug....

Amryt Submits a New Drug Application to the US Food and Drug Administration for...

TW's Take: if approved, Oleogel-S10 is likely to become Amryt's largest drug franchise in very short order. Expect to hear about the acceptance and...

Amryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS

TW's Take: very encouraging data as a label expansion into FCS would potentially double the addressable market for the drug. Amryt continues to increase...

Orlando Court to Reschedule Trial; Company Raises $3.6 Million in Private Placement

TW's Take: solid news that the company has raised some capital and this, "we remain confident that we will soon have new licensees of...

Amryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)

TW's Take: further progress as they march towards hopeful approval in EB, which should make Oleogel-S10 their largest product in short order. DUBLIN, Ireland, and...

2nd Degree of Risk

Investing in micro-caps always involves a high degree of risk. This risk can come in many different forms as well. For example, looking at...

TFF Pharmaceuticals Prices Offering of Common Stock

TW's Take: enough cash to bring in another program, created an internal sterile vaccine line and last until 2024 is a good thing at...

This Week’s View On Anixa

A week in the market seems like an eternity these days, right? I mean, just last week Anixa (ANIX) was trading at $8 a share....

WiSA Member Foxconn Demos Sharp 120-Inch 8K TV with WiSA SoundSend and Wireless Audio...

TW's Take: the future for high-end TVs is speakerless and WiSA is the easiest, best sounding and cheapest solution on the market. Continued traction...

Become a TW Research Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $500 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.